229 patents
Page 2 of 12
Utility
Targeting dimerization of BAX to modulate BAX activity
19 Sep 23
Methods are provided for identifying an agent that directly modulates a Bcl-2-associated x-protein (BAX) by promoting or disrupting dimerization of the BAX.
Evripidis Gavathiotis
Filed: 19 Mar 19
Utility
Inhibition of Bax-mediated Cell Death by Eltrombopag
31 Aug 23
This disclosure provides methods for inhibiting BAX activity and BAX-mediated apoptosis, as well as methods for treating or preventing BAX-mediated disorders, based, in part, on an unexpected discovery that eltrombopag (EO) can work as as a potent binder to the BAX trigger site and an effective direct BAX inhibitor.
Evripidis Gavathiotis
Filed: 15 Apr 21
Utility
7nlalrwxpoqldj4b zxj5fqejjr2sb0529wnntn
22 Aug 23
Antibodies and antibody fragments that inhibit the activity of vascular cell adhesion molecule 1 (VCAM1) and/or macrophage erythroblast attacher (MAEA) are provided, along with formulations and kits comprising these antibodies and antibody fragments and the use of the disclosed compositions, formulations, and kits to treat cancers, sickle cell disease, and Polycythemia Vera.
Paul S. Frenette, Sandra Pinho, Qiaozhi Wei
Filed: 1 Oct 20
Utility
2ffzefs82mjzsyxbwejly106r768hy
17 Aug 23
Heritable mutations in the BRCA1 and BRCA2 and other genes in the DNA double-strand break (DSB) repair pathway increase risk of breast, ovarian and other cancers.
Harry OSTRER, Johnny C. LOKE, Alexander PEARLMAN
Filed: 6 Apr 23
Utility
cxukhf57zcsotbqzme5df42n29w0ilek0a5myd3581ha
15 Aug 23
Methods and devices are disclosed for intra-operative viewing of pre- and intra-operative 3D patient images.
Oren Mordechai Tepper, Jillian Schreiber, Cesar Colasante
Filed: 2 Oct 20
Utility
o3frumh urx4f3wxa7bgpo
15 Aug 23
Small molecule agonists of the pregnane X receptor (PXR), compositions and methods are disclosed for treating or preventing gut barrier dysfunction, an illness associated with gut barrier dysfunction, toxic or inflammatory injury to intestines, or leaky intestinal (gut) syndrome in a subject.
Sridhar Mani, Felix Kopp, Zdenek Dvorak, Sandhya Kortagere, Chamini Karunaratne
Filed: 18 Jan 18
Utility
xzxi0r0tsg950x svhmp9vao7ldcb3
1 Aug 23
Methods and apparatus are provided for high resolution intravital imaging and for chronic optical imaging of tissues such as lung.
David Entenberg, John S. Condeelis, Sonia E. Voiculescu
Filed: 1 Aug 18
Utility
6ovii0qhd1pc5hnxepbu46x9x2k37lp2dxx8k7s4ve2iis9hfio7uoj2j
1 Aug 23
Methods are provided for using 3-OH-kynurenamine to treat and prevent an inflammatory or autoimmune disease or disorder or transplant rejection, and for promoting immune tolerance.
Laura Santambrogio
Filed: 12 Mar 19
Utility
tkv2bqbku9t1 nza7k93naacae
13 Jul 23
Methods and kits are disclosed for measuring activity of a methyltransferase or a radical SAM enzyme or for screening for an inhibitor of a methyltransferase or a radical SAM enzyme, where the methods and kits comprise, respectively, deaminase TM0936 for a MTase coupled assay and deaminase PA3170 for a radical SAM coupled assay.
Emmanuel Sebastien BURGOS, David SHECHTER
Filed: 20 Feb 18
Utility
ah3fthjs7g4ub8kd241msf2rwrykzyjn5norxz33a
6 Jul 23
Antibodies and antibody fragments that inhibit the activity of vascular cell adhesion molecule 1 (VCAM1) and/or macrophage erythroblast attacher (MAEA) are provided, along with formulations and kits comprising these antibodies and antibody fragments and the use of the disclosed compositions, formulations, and kits to treat cancers, sickle cell disease, and Polycythemia Vera.
Paul S. FRENETTE, Sandra PINHO, Qiaozhi WEI, Sung Kyun LEE
Filed: 27 Dec 22
Utility
ubhdx3q6u6m72jbs6itrykmdq8gn1wnadx7o r4olqqq
27 Jun 23
Methods of vaccinating, immunizing and/or treating a subject against a herpes simplex virus infection or a disease caused by a herpes simplex virus infection comprise administering to the subject an effective amount of a HSV-2 single-cycle virus and an effective amount of a recombinant HSV-2 glycoprotein D, wherein the HSV-2 single-cycle virus comprises HSV-2 having a deletion of glycoprotein D-encoding gene in the genome and the HSV-2 is phenotypically complemented with an HSV-1 glycoprotein D on a lipid bilayer of the HSV-2.
Betsy C. Herold, Clare Burn Aschner
Filed: 1 Jun 21
Utility
10sv77nyl716uq6tyira0t9 gzydxzz46jx6dmu0
16 May 23
Heritable mutations in the BRCA1 and BRCA2 and other genes in the DNA double-strand break (DSB) repair pathway increase risk of breast, ovarian and other cancers.
Harry Ostrer, Johnny C. Loke, Alexander Pearlman
Filed: 12 Jun 20
Utility
539a41tyn0 pqh14rm7vzqg6p1am2pn98o9
9 May 23
Provided are high affinity Mycobacterium tuberculosis capsule-specific antibodies and fragments thereof, as well as methods of use and devices employing such antibodies and/or fragments.
Jacqueline M. Achkar, Jonathan Lai, Elise Ishida, Daniel Hofmann, Tingting Chen
Filed: 15 Dec 20
Utility
bcy6a1mc7demymdjwwr0rym4ivtnltgad52471a5h1rpgu7 qi8
27 Apr 23
Methods for activating pregnane X receptor (PXR) using co-muricholic acid thereby treating metabolic syndrome, obesity, inflammatory bowel disease, Crohn’s disease, and liver disease, and also thereby increasing CYP3A4 gene and/or protein expression.
Julia Yue Cui, Sridhar Mani, Moumita Dutta
Filed: 21 Oct 22
Utility
em8nsit7so6pt6re09qtiqskzinxpwirt2
27 Apr 23
The present disclosure relates to a method of modulating one or more genetically modified cells, e.g., chimeric antigen receptor (CAR)-expressing cells, ex vivo and/or in vivo.
Harris GOLDSTEIN, Steven C ALMO, Scott GARFORTH, Mengyan LI
Filed: 8 Mar 21
Utility
u4q3uoohppzfe5m85pmd3 ry4v531
20 Apr 23
A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided.
Joel M. Friedman
Filed: 31 Oct 22
Utility
gmhh5slnnk0fxdnsdd7mhf5qj0d45x
13 Apr 23
Provided are isolated antibodies and antigen-binding fragments thereof that specifically bind CEACAM1, including the IgV domain of CEACAM1, as well as pharmaceutical formulations, kits, and methods of use thereof.
Xingxing ZANG
Filed: 29 Jun 22
Utility
zn2945heoumju63ulzapiuz5ht6cx3z0xcypxqr
13 Apr 23
Methods of treating or preventing ocular disease caused by herpes simplex virus-1 infection are provided, and comprise administering to a subject an effective amount of a herpes simplex virus-2 (HSV-2) having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome to treat or prevent ocular disease in the subject, wherein the HSV-2 is phenotypically complemented with an HSV-1 glycoprotein D by propagating the HSV-2 in a complementing cell expressing the HSV-1 glycoprotein D.
Betsy C. Herold
Filed: 7 Apr 21
Utility
wucrhpx4fv0rfic6hrzlreq089yf3u0s5tnoyxenlhj
9 Mar 23
Provided are methods of treating an autoimmune disease in a subject, or of suppressing transplant rejection in a subject, or of treating a cancer in a subject, as well as compositions therefor.
Xingxing ZANG
Filed: 15 Sep 22
Utility
qjjw6k40w6h5ahjw42h77cdfh6law13m0h2q
7 Mar 23
Microvesicles produced by stem cells grown on a silk scaffold for enhancing stem cell self-renewal/proliferation and promoting tenogenesis in damaged tendons, and their use in tendon wound repair and tendinopathy treatment.
Hui B. Sun
Filed: 21 Aug 17